EP Patent

EP2847194B1 — Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide

Assigned to AstraZeneca AB · Expires 2017-10-04 · 9y expired

What this patent protects

Patent listed against null.

Drugs covered by this patent

Patent Metadata

Patent number: EP2847194B1
Jurisdiction: EP
Classification: —
Expires: 2017-10-04
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.